28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2) - 07/08/21
Doi : 10.1016/j.jaad.2021.06.723
Andreas Wollenberg
Prof Dr med Dr hc, Department of Dermatology and Allergology, Ludwig-Maximilian University of Munich
Andrew Pink, BMedSci (Hons), BMBS, PhD, MRCP
St. John’s Institute of Dermatology, Guy’s and St. Thomas’ Hospitals
Ketty Peris, MD, PhD
Dermatology, Catholic University and Fondazione Policlinico Universitario A. Gemelli, IRCCS
April Armstrong, MD, MPH
Department of Dermatology, Keck School of Medicine at the University of Southern California
Charles Lynde, MD, FRCPC
FCDA, Lynde Dermatology, Probity Medical Research and Department of Medicine, University of Toronto
Le texte complet de cet article est disponible en PDF.
| Commercial Disclosure: The ECZTRA 1 and 2 studies were sponsored by LEO Pharma. Medical writing and editorial assistance were provided by Kathryn Woods and Lauren Smith, from McCann Health, funded by LEO Pharma. |
© 2021
Publié par Elsevier Masson SAS.
Vol 85 - N° 3S
P. AB177 - septembre 2021 Retour au numéro
Article précédent
- 28170 Neutralizing interleukin-13 increases skin microbial diversity: Results from a phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis
- Thomas Bieber, Lisa A. Beck, Andrew Pink, Hidehisa Saeki, Lawrence Eichenfield, Thomas Werfel, Anders Rosholm, Mads Røpke, Amy Paller
- 28179 Effectiveness of a skincare product on relieving the symptoms of neonatal and infantile acne and its impact on QoL
- Sophie Seite
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?